<p>Evernest Financial Advisors LLC 在最近向證券交易委員會提交的 13F 文件中披露，其在禮來的股份（NYSE:LLY - 免費報告）中持股比例在第一季度增加了 8.1%。該公司在本季度額外購買了 360 股後，持有該公司 4,779 股股票。禮來公司佔 Evernest Financial Advisors LLC 投資組合的 1.4%，是其第 19 大持倉。截至最近向證券交易委員會提交的文件，Evernest Financial Advisors LLC 在禮來公司的持股價值為 3,947,000 美元。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<ul>
<li>諾和諾德股票下跌——但底部終於到來了嗎？</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也調整了對 LLY 的持股。WestEnd Advisors LLC 在第一季度將其在禮來公司的持倉增加了 210.0%。WestEnd Advisors LLC 現在擁有 31 股該公司的股票，價值 26,000 美元，此前在上個季度額外購買了 21 股。Citizens National Bank Trust Department 在第一季度將其在禮來公司的股份增加了 180.0%。Citizens National Bank Trust Department 現在擁有 42 股該公司的股票，價值 35,000 美元，此前在此期間額外購買了 27 股。Financial Gravity Asset Management Inc.在第一季度購買了禮來公司的新頭寸，價值 40,000 美元。Mascagni Wealth Management Inc.在第四季度購買了禮來公司的新股份，價值約 43,000 美元。最後，O Brien Wealth Partners LLC 在第一季度將其在禮來公司的持倉增加了 25.5%。O Brien Wealth Partners LLC 現在擁有 59 股該公司的股票，價值 49,000 美元，此前在上個季度額外購買了 12 股。82.53% 的股票由機構投資者持有。</p>
<h2>禮來公司股票下跌 2.6%</h2>
<p>NYSE:LLY 的股票在週四開盤價為 746.17 美元。該公司的 50 日簡單移動平均為 777.97 美元，200 日簡單移動平均為 800.20 美元。該公司的速動比率為 1.06，流動比率為 1.37，債務與股本比率為 2.18。該公司的市值為 7071.7 億美元，市盈率為 60.71，市盈增長比率為 1.09，貝塔值為 0.44。禮來公司的 12 個月低點為 677.09 美元，12 個月高點為 972.53 美元。</p>
<h2>禮來公司宣佈分紅</h2>
<ul>
<li>醫療保健股票估值觸底，3 只股票有望反彈</li>
</ul>
<p>該公司最近還宣佈了一項季度分紅，將於 9 月 10 日（星期三）支付。8 月 15 日（星期五）登記在冊的股東將獲得 1.50 美元的分紅。除息日期為 8 月 15 日（星期五）。這代表着年化分紅為 6.00 美元，分紅收益率為 0.8%。禮來公司的派息比率為 48.82%。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位分析師最近對 LLY 股票發表了看法。摩根士丹利在 7 月 10 日的報告中重申了 “增持” 評級，並將禮來公司的目標價從 1,133.00 美元上調至 1,135.00 美元。滙豐銀行將禮來公司的評級從 “買入” 下調至 “減持”，並在 4 月 28 日的報告中將其目標價從 1,150.00 美元下調至 700.00 美元。古根海姆在 7 月 11 日的報告中將禮來公司的目標價從 936.00 美元上調至 942.00 美元，並給予該股票 “買入” 評級。Cantor Fitzgerald 在 4 月 22 日的研究報告中開始覆蓋禮來公司的股票，設定了 “增持” 評級和 975.00 美元的目標價。最後，Erste Group Bank 在 6 月 5 日的研究報告中將禮來公司的評級從 “買入” 下調至 “持有”。一位分析師對該股票給予了賣出評級，三位分析師給予了持有評級，十七位分析師給予了買入評級。根據 MarketBeat 的數據，禮來公司的平均評級為 “適度買入”，平均目標價為 1,012.56 美元。</p>
<ul>
<li>高盛在其看漲的標準普爾 500 展望中重點關注這 3 只股票</li>
</ul>
<p><strong>獲取我們對禮來公司的最新分析</strong></p>
<h2>禮來公司簡介</h2>
<p>（免費報告）</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過禮來公司</li>
<li>如何交易便士股票：逐步指南</li>
<li>買入下跌？這些盈利失誤提供長期上漲潛力</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>RSI 股票在第二季度暴漲 22%——PENN 會跟上這種勢頭嗎？</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>DigitalOcean 的專注如何推動爆炸性增長</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮投資禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而禮來公司並不在名單上。</p>
<p>雖然禮來公司的分析師評級為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>Evernest Financial Advisors LLC 在第一季度將其在禮來公司（NYSE: LLY）的持股增加了 8.1%，額外購買了 360 股，總持股達到 4,779 股，價值約為 395 萬美元。禮來在 Evernest 的投資組合中佔比 1.4%。該股票目前下跌 2.6%，交易價格為 746.17 美元，市值為 7071.7 億美元。分析師的評級不一，平均目標價為 1,012.56 美元，顯示出 “適度買入” 的情緒</p>

<p>Evernest Financial Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,779 shares of the company's stock after buying an additional 360 shares during the quarter. Eli Lilly and Company comprises 1.4% of Evernest Financial Advisors LLC's portfolio, making the stock its 19th biggest position. Evernest Financial Advisors LLC's holdings in Eli Lilly and Company were worth $3,947,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Evernest Financial Advisors LLC 在最近向證券交易委員會提交的 13F 文件中披露，其在禮來的股份（NYSE:LLY - 免費報告）中持股比例在第一季度增加了 8.1%。該公司在本季度額外購買了 360 股後，持有該公司 4,779 股股票。禮來公司佔 Evernest Financial Advisors LLC 投資組合的 1.4%，是其第 19 大持倉。截至最近向證券交易委員會提交的文件，Evernest Financial Advisors LLC 在禮來公司的持股價值為 3,947,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德股票下跌——但底部終於到來了嗎？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department boosted its stake in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth $40,000. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. Finally, O Brien Wealth Partners LLC lifted its position in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the last quarter. 82.53% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也調整了對 LLY 的持股。WestEnd Advisors LLC 在第一季度將其在禮來公司的持倉增加了 210.0%。WestEnd Advisors LLC 現在擁有 31 股該公司的股票，價值 26,000 美元，此前在上個季度額外購買了 21 股。Citizens National Bank Trust Department 在第一季度將其在禮來公司的股份增加了 180.0%。Citizens National Bank Trust Department 現在擁有 42 股該公司的股票，價值 35,000 美元，此前在此期間額外購買了 27 股。Financial Gravity Asset Management Inc.在第一季度購買了禮來公司的新頭寸，價值 40,000 美元。Mascagni Wealth Management Inc.在第四季度購買了禮來公司的新股份，價值約 43,000 美元。最後，O Brien Wealth Partners LLC 在第一季度將其在禮來公司的持倉增加了 25.5%。O Brien Wealth Partners LLC 現在擁有 59 股該公司的股票，價值 49,000 美元，此前在上個季度額外購買了 12 股。82.53% 的股票由機構投資者持有。</p>
</div><h2>Eli Lilly and Company Stock Down 2.6%</h2>
<div class="lb-trans"><h2>禮來公司股票下跌 2.6%</h2>
</div><p>Shares of NYSE:LLY opened at $746.17 on Thursday. The business has a fifty day simple moving average of $777.97 and a 200 day simple moving average of $800.20. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm has a market cap of $707.17 billion, a P/E ratio of 60.71, a P/E/G ratio of 1.09 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.</p>
<div class="lb-trans"><p>NYSE:LLY 的股票在週四開盤價為 746.17 美元。該公司的 50 日簡單移動平均為 777.97 美元，200 日簡單移動平均為 800.20 美元。該公司的速動比率為 1.06，流動比率為 1.37，債務與股本比率為 2.18。該公司的市值為 7071.7 億美元，市盈率為 60.71，市盈增長比率為 1.09，貝塔值為 0.44。禮來公司的 12 個月低點為 677.09 美元，12 個月高點為 972.53 美元。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>禮來公司宣佈分紅</h2>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>醫療保健股票估值觸底，3 只股票有望反彈</li>
</ul>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 48.82%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 9 月 10 日（星期三）支付。8 月 15 日（星期五）登記在冊的股東將獲得 1.50 美元的分紅。除息日期為 8 月 15 日（星期五）。這代表着年化分紅為 6.00 美元，分紅收益率為 0.8%。禮來公司的派息比率為 48.82%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several analysts recently weighed in on LLY shares. Morgan Stanley reissued an &#34;overweight&#34; rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. HSBC lowered Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;reduce&#34; rating and reduced their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim upped their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 11th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an &#34;overweight&#34; rating and a $975.00 price objective for the company. Finally, Erste Group Bank lowered Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,012.56.</p>
<div class="lb-trans"><p>幾位分析師最近對 LLY 股票發表了看法。摩根士丹利在 7 月 10 日的報告中重申了 “增持” 評級，並將禮來公司的目標價從 1,133.00 美元上調至 1,135.00 美元。滙豐銀行將禮來公司的評級從 “買入” 下調至 “減持”，並在 4 月 28 日的報告中將其目標價從 1,150.00 美元下調至 700.00 美元。古根海姆在 7 月 11 日的報告中將禮來公司的目標價從 936.00 美元上調至 942.00 美元，並給予該股票 “買入” 評級。Cantor Fitzgerald 在 4 月 22 日的研究報告中開始覆蓋禮來公司的股票，設定了 “增持” 評級和 975.00 美元的目標價。最後，Erste Group Bank 在 6 月 5 日的研究報告中將禮來公司的評級從 “買入” 下調至 “持有”。一位分析師對該股票給予了賣出評級，三位分析師給予了持有評級，十七位分析師給予了買入評級。根據 MarketBeat 的數據，禮來公司的平均評級為 “適度買入”，平均目標價為 1,012.56 美元。</p>
</div><ul>
<li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>高盛在其看漲的標準普爾 500 展望中重點關注這 3 只股票</li>
</ul>
</div><p><strong>Get Our Latest Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>獲取我們對禮來公司的最新分析</strong></p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>禮來公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>Buy the Dip? These Earnings Misses Offer Long-Term Upside</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>How DigitalOcean's Focus Is Fueling Explosive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過禮來公司</li>
<li>如何交易便士股票：逐步指南</li>
<li>買入下跌？這些盈利失誤提供長期上漲潛力</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>RSI 股票在第二季度暴漲 22%——PENN 會跟上這種勢頭嗎？</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>DigitalOcean 的專注如何推動爆炸性增長</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司的分析師評級為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Evernest Financial Advisors LLC 購入了禮來公司（NYSE:LLY）的 360 股股票